PA8814801A1 - Triazolopiridazinas como inhibidores de par1, su preparación y su uso como medicamentos - Google Patents

Triazolopiridazinas como inhibidores de par1, su preparación y su uso como medicamentos

Info

Publication number
PA8814801A1
PA8814801A1 PA20098814801A PA8814801A PA8814801A1 PA 8814801 A1 PA8814801 A1 PA 8814801A1 PA 20098814801 A PA20098814801 A PA 20098814801A PA 8814801 A PA8814801 A PA 8814801A PA 8814801 A1 PA8814801 A1 PA 8814801A1
Authority
PA
Panama
Prior art keywords
medications
preparation
triazolopiridazinas
par1 inhibitors
par1
Prior art date
Application number
PA20098814801A
Other languages
English (en)
Inventor
Heinelt Uwe
Wehner Volkmar
Herrmann Matthias
Schoenafinger Karl
Steinhagen Henning
Scheiper Bodo
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PA8814801A1 publication Critical patent/PA8814801A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCIÓN SE REFIERE A COMPUESTOS DE FÓRMULA I CON ACTIVIDAD ANTTROMBÓTICA,QUE INHIBEN ESPECIALMENTE EL RECEPTOR 1 ACTIVADO POR PROTEASA,A MÉTODOS PARA SU PREPARACIÓN Y A SU USO COMO MEDICAMENTOS.
PA20098814801A 2008-02-05 2009-02-03 Triazolopiridazinas como inhibidores de par1, su preparación y su uso como medicamentos PA8814801A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08290112 2008-02-05

Publications (1)

Publication Number Publication Date
PA8814801A1 true PA8814801A1 (es) 2009-09-17

Family

ID=39539711

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098814801A PA8814801A1 (es) 2008-02-05 2009-02-03 Triazolopiridazinas como inhibidores de par1, su preparación y su uso como medicamentos

Country Status (32)

Country Link
US (2) US8076336B2 (es)
EP (1) EP2240487B1 (es)
JP (1) JP5526040B2 (es)
KR (1) KR20100114514A (es)
CN (1) CN101981034B (es)
AR (1) AR070410A1 (es)
AT (1) ATE537172T1 (es)
AU (1) AU2009211887B2 (es)
BR (1) BRPI0907486A2 (es)
CA (1) CA2713550C (es)
CL (1) CL2009000236A1 (es)
CO (1) CO6260083A2 (es)
CY (1) CY1113228T1 (es)
DK (1) DK2240487T3 (es)
ES (1) ES2379447T3 (es)
HK (1) HK1149011A1 (es)
HR (1) HRP20120230T1 (es)
IL (1) IL207205A0 (es)
MA (1) MA32061B1 (es)
MX (1) MX2010008490A (es)
MY (1) MY152040A (es)
NZ (1) NZ587141A (es)
PA (1) PA8814801A1 (es)
PE (1) PE20091455A1 (es)
PL (1) PL2240487T3 (es)
PT (1) PT2240487E (es)
RS (1) RS52264B (es)
RU (1) RU2499797C2 (es)
SI (1) SI2240487T1 (es)
TW (1) TW200946532A (es)
WO (1) WO2009097970A1 (es)
ZA (1) ZA201004467B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007297754B2 (en) * 2006-09-18 2012-05-17 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of c-MET and uses thereof
CN101981035B (zh) * 2008-02-05 2013-08-28 赛诺菲-安万特 作为par1抑制剂的****盐、其制备及其作为药物的用途
US8673890B2 (en) 2009-10-29 2014-03-18 Janssen Pharmaceutica Nv 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578464A (en) 1983-11-22 1986-03-25 Merrell Dow Pharmaceuticals Inc. 6-Hydroxyalkylamino-8-methyl-1,2,4-triazolo-[4,3-b]pyridazine and related compounds
CN1046517C (zh) * 1994-09-16 1999-11-17 武田药品工业株式会社 ***并哒嗪,其制备和应用
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
US7488742B2 (en) 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
IL158491A0 (en) * 2001-04-19 2004-05-12 Eisai Co Ltd 2-iminopyrrolidine derivatives
US6956046B2 (en) 2001-05-25 2005-10-18 Mochida Pharmaceutical Co., Ltd. 4-hydroxypiperidine derivatives having analgesic activity
WO2003031442A1 (fr) 2001-10-05 2003-04-17 Takeda Chemical Industries, Ltd. Composes heterocycliques, derives oxazole, procede permettant de les presenter et leur utilisation
ATE525378T1 (de) 2001-10-18 2011-10-15 Schering Corp Himbacinanaloga als thrombinrezeptorantagonisten
CA2482858C (en) 2002-04-16 2010-11-30 Schering Corporation Tricyclic thrombin receptor antagonists
JP4549970B2 (ja) 2003-02-19 2010-09-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 環状ベンズアミジン誘導体の製造方法
TW200531688A (en) 2004-03-05 2005-10-01 Hoffmann La Roche Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
EP1813282A4 (en) 2004-11-09 2011-03-02 Eisai R&D Man Co Ltd MEANS FOR THE TREATMENT OF ANGIOSPASM IN SUBARACHO-OAL BLOODING WITH THROMBIN RECEPTOR ANTAGONIST AS AN ACTIVE AGENT
AP3433A (en) * 2005-12-21 2015-10-31 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modultors
DE102006025318A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Dihydro-pyrrolopyridin-, Dihydro-pyrrolopyridazin- und Dihydro-pyrrolopyrimidin-Derivate und ihre Verwendung
DE102006036023A1 (de) * 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
CN101981035B (zh) 2008-02-05 2013-08-28 赛诺菲-安万特 作为par1抑制剂的****盐、其制备及其作为药物的用途
SI2242740T1 (sl) 2008-02-05 2013-03-29 Sanofi SF5-derivati kot PAR1 inhibitorji, njihova priprava in uporaba kot zdravila
ES2603302T3 (es) 2008-02-05 2017-02-24 Sanofi Imidazopiridazinas como inhibidores de PAR1, su obtención y empleo como medicamento
US8324241B2 (en) 2008-04-11 2012-12-04 Bristol-Myers Squibb Company Triazolo compounds useful as DGAT1 inhibitors
WO2009126861A2 (en) 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolopyridine compounds useful as dgat1 inhibitors

Also Published As

Publication number Publication date
US20120010203A1 (en) 2012-01-12
RU2499797C2 (ru) 2013-11-27
IL207205A0 (en) 2010-12-30
EP2240487B1 (de) 2011-12-14
SI2240487T1 (sl) 2012-04-30
MA32061B1 (fr) 2011-02-01
WO2009097970A1 (de) 2009-08-13
CN101981034A (zh) 2011-02-23
CO6260083A2 (es) 2011-03-22
CA2713550C (en) 2016-06-14
CA2713550A1 (en) 2009-08-13
TW200946532A (en) 2009-11-16
BRPI0907486A2 (pt) 2015-07-14
ES2379447T3 (es) 2012-04-26
ATE537172T1 (de) 2011-12-15
PE20091455A1 (es) 2009-10-22
KR20100114514A (ko) 2010-10-25
DK2240487T3 (da) 2012-04-02
JP5526040B2 (ja) 2014-06-18
MY152040A (en) 2014-08-15
AU2009211887A1 (en) 2009-08-13
PT2240487E (pt) 2012-03-08
MX2010008490A (es) 2010-08-18
CY1113228T1 (el) 2016-04-13
HRP20120230T1 (hr) 2012-04-30
US8076336B2 (en) 2011-12-13
CN101981034B (zh) 2013-08-14
JP2011511016A (ja) 2011-04-07
RU2010136957A (ru) 2012-03-20
ZA201004467B (en) 2011-09-28
HK1149011A1 (en) 2011-09-23
RS52264B (en) 2012-10-31
AR070410A1 (es) 2010-04-07
NZ587141A (en) 2012-04-27
US20110034451A1 (en) 2011-02-10
PL2240487T3 (pl) 2012-05-31
EP2240487A1 (de) 2010-10-20
US9079906B2 (en) 2015-07-14
CL2009000236A1 (es) 2009-06-05
AU2009211887B2 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
CL2007002682A1 (es) Compuestos derivados de 4-metilpiridopirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el crecimiento anormal de celulas, como cancer.
UY39963A (es) Composiciones herbicidas a base de carbamoíltriazolinona y métodos de uso
BRPI0921063B8 (pt) composto, e, composição agonística para receptor de melanocortina
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
PA8827101A1 (es) Derivados de indazoles sustituidos con fenilo o piridinilo
CL2013002171A1 (es) Composicion fungicida y bactericida que comprende compuestos organicos volatiles de origen natural; uso de la composición.
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
HN2008001723A (es) Nitrilos espirociclicos como inhibidores de proteasa
CL2008003690A1 (es) Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos.
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
SV2010003593A (es) Nuevos herbicidas
CL2014003191A1 (es) Compuestos que inhiben la actividad de catecol o -metiltransferasa; su uso contra el parkinson.
GT200900315A (es) Inhibición de arni de expresión de alfa-enac
NI201000035A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
CL2007002519A1 (es) Compuestos derivados de aminopiridina, inhibidores selectivo sobre aurora a; composicion farmaceutica que comprende a dichos compuestos; combinacion farmaceutica que comprende a dichos compuestos, utiles para inhibir el crecimiento de celulas tumoral
CL2008002041A1 (es) Compuestos derivados de piperidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar ansiedad.
GT201000047A (es) Mejoras en compuestos organicos o relacionadas con los mismos
NI201000036A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
CL2009000904A1 (es) Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
CL2008000090A1 (es) Compuestos derivados de piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso como inhibidores del receptor p2y 12 para tratar un trastorno de agragacion de plaquetas.
CL2008000093A1 (es) Compuestos derivados de piridina, inhibidores de p2y12; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de un desorden de agregacion plaquetaria.
PA8814801A1 (es) Triazolopiridazinas como inhibidores de par1, su preparación y su uso como medicamentos
ATE533477T1 (de) Pharmazeutische zusammensetzungen enthaltend irbesartan